AnaptysBio (NASDAQ:ANAB) Director Hollings Renton Sells 5,000 Shares of Company Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the completion of the sale, the director owned 10,995 shares of the company’s stock, valued at $548,320.65. The trade was a 31.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB traded down $0.10 during trading on Friday, reaching $48.53. The company had a trading volume of 441,119 shares, compared to its average volume of 693,818. AnaptysBio, Inc. has a 52 week low of $19.65 and a 52 week high of $72.36. The stock has a market cap of $1.45 billion, a PE ratio of 9.04 and a beta of 0.76. The business’s 50 day moving average price is $55.15 and its 200-day moving average price is $58.69.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 EPS for the quarter, beating the consensus estimate of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The business had revenue of $27.49 million for the quarter, compared to analysts’ expectations of $14.06 million. During the same period in the prior year, the firm earned ($1.30) earnings per share. Equities analysts anticipate that AnaptysBio, Inc. will post -1.3 earnings per share for the current year.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. First Light Asset Management LLC boosted its stake in AnaptysBio by 2.9% in the second quarter. First Light Asset Management LLC now owns 582,004 shares of the biotechnology company’s stock valued at $39,285,000 after acquiring an additional 16,573 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of AnaptysBio by 21.2% during the 2nd quarter. Squarepoint Ops LLC now owns 324,446 shares of the biotechnology company’s stock valued at $21,900,000 after acquiring an additional 56,743 shares during the last quarter. Arizona State Retirement System lifted its stake in shares of AnaptysBio by 13.5% in the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after purchasing an additional 518 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of AnaptysBio in the 2nd quarter valued at $1,164,000. Finally, Irenic Capital Management LP bought a new position in shares of AnaptysBio in the 2nd quarter worth $4,755,000.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ANAB shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of AnaptysBio in a research report on Tuesday, September 22nd. Wolfe Research restated an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a research report on Monday, August 31st. TD Cowen cut their price target on AnaptysBio from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a report on Tuesday, September 22nd. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average target price of $77.79.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for inflammatory and autoimmune diseases. The company uses its antibody discovery and engineering capabilities to identify therapies designed to modulate immune-system targets involved in disease.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to target CD200R1, a receptor involved in regulating immune-cell activity. The company has evaluated rosnilimab in inflammatory and autoimmune conditions, including rheumatoid arthritis and ulcerative colitis.